Sumitomo Dainippon Pharma Co., Ltd.

49 articles about Sumitomo Dainippon Pharma Co., Ltd.

• 

  Sunovion Submits NDA for Sublingual Parkinson's Treatment

  3/30/2018

  Sunovion Pharmaceuticals announced it submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).

• Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase III Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

  12/27/2017

  In December 2017, the first patient was included in the TIMES 1 trial, a multicenter, double-blind, placebo-controlled, randomized, monotherapy study in over 200 Japanese patients with type 2 diabetes.

• 

  Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact

  10/30/2017

  The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan.

• Sharp Edge Labs Enters Into Drug Discovery Collaboration With Sumitomo Dainippon Pharma

  1/3/2017

• 295 Sumitomo Dainippon Pharma Employees Take Early Retirement

  10/21/2016

• GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com

  6/6/2016

• Elixirgen Announces License Agreement With Sumitomo Dainippon Pharma Co., Ltd.

  11/19/2015

• ex scientia Ltd. Reaches First Delivery Milestone In Collaboration With Sumitomo Dainippon Pharma Co., Ltd.

  9/2/2015

• Sumitomo Dainippon Pharma Co., Ltd. , Takeda Terminate Latuda Agreement

  5/7/2015